PARP1 and ovarian cancer: The ATR inhibitor ceralasertib enhances the efficacy of PARP inhibitors in homologous recombination deficient (HRD) ovarian cancer by inhibiting the DNA damage response (DDR) pathway (NCT03462342) (124–135).